Galectin Therapeutics (GALT) Price Target Lowered by Analysts At MLV & Co

Galectin Therapeutics (GALT) is one of today’s biggest pre-market movers, down a mind-boggling 60% to $5.75. Late Tuesday, Galectin shares started to nosedive after the drug development company reported poor results in Phase 1 trial of its experimental GR-MD-02 (GR02) drug for treatment of a fatty liver disease. Following the announcement, equities research analysts at […] View the full post at: Galectin Therapeutics (GALT) Price Target Lowered by Analysts At MLV & Co Related posts: Edward Zabitsky Recommends Selling Apple (AAPL) Short, $126 Target Moody’s: Greece’s New Austerity Measures Lend Credibility to Fiscal Adjustment Plan